Are you Dr. Haluska?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
750 Washington St
Nemc Box #836
Boston, MA 02111Phone+1 617-636-5000
Summary
- Dr. Frank Haluska, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1995
Massachusetts General HospitalResidency, Internal Medicine, 1989 - 1991
Perelman School of Medicine at the University of PennsylvaniaClass of 1989
Certifications & Licensure
MA State Medical License 1991 - 2025
Clinical Trials
- S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Start of enrollment: 2000 Aug 01
- Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) Start of enrollment: 2003 May 01
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 33 citationsEffects of food on the pharmacokinetics of ponatinib in healthy subjectsNarayana I. Narasimhan, David J. Dorer, Katie Niland, Frank G. Haluska, Daryl Sonnichsen
Journal of Clinical Pharmacy and Therapeutics. 2013-12-01 - 765 citationsA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasJorge E. Cortes, Dong-Kee Kim, Javier Pinilla-Ibarz, P. le Coutre, Ronald Paquette
The New England Journal of Medicine. 2013-11-06 - 359 citationsPonatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialJorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette
Blood. 2018-07-26
Press Mentions
Anchiano Appoints Steve DiPalma as Chief Financial OfficerMay 5th, 2020
Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare ConferenceSeptember 20th, 2019- Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment ConferenceSeptember 3rd, 2019
- Join now to see all
Grant Support
- Genetics Of RAS, PTEN, BRAF And CDKN2A In MelanomaNational Cancer Institute2006
- Genetics Of RAS, PTEN, BRAF And CDKN2A In MelanomaNational Cancer Institute2005
- Peptide-Pulsed Dendritic Cell Therapy For MelanomaNational Cancer Institute1999–2000
